Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Masahiro Tanemura

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110015952. Sources: OpenAlex.

Their work

Papers
37 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 3 papers · 2014: 2 papers · 2015: 3 papers · 2016: none · 2017: 8 papers · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 5 papers · 2024: 4 papers · 2025: 1 paper · 2026: 1 paper

Papers 37

  1. Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Co-author DOI 10.1371/journal.pone.0345459↗
  2. Post hoc subgroup analysis of neoadjuvant gemcitabine plus S1 vs gemcitabine plus nab paclitaxel in elderly resectable/borderline resectable pancreatic adenoca… Co-author DOI 10.1038/s41598-025-23185-7↗
  3. Removal of gemcitabine-induced senescent cancer cells by targeting glutaminase1 improves the therapeutic effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.34725↗
  4. Clinical impact of high-quality testing for peritoneal lavage cytology in pancreatic cancer. Co-author DOI 10.1038/s41598-024-60936-4↗
  5. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline… Co-author DOI 10.1245/s10434-024-15199-8↗
  6. ASO Author Reflections: Which was the Better Regimen (Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1) as Neoadjuvant Chemotherapy for Localized Pa… Co-author DOI 10.1245/s10434-024-15244-6↗
  7. Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-023-04531-w↗
  8. Pancreatic cancer near the splenic hilum has a higher likelihood of splenic vessel invasion and unfavorable survival. Co-author DOI 10.1007/s00423-023-03089-8↗
  9. Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy. Co-author DOI 10.1007/s10147-023-02306-0↗
  10. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma U… Co-author DOI 10.1245/s10434-022-12985-0↗
  11. ASO Author Reflections: Neoadjuvant Chemoradiotherapy for Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancre… Co-author DOI 10.1245/s10434-022-13024-8↗
  12. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11668-0↗
  13. ASO Author Reflections: A Novel Mechanism of Suppressing Proliferation After Inhibition of Clusterin in Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11745-4↗
  14. Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2021.04.029↗
  15. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadj… Co-author DOI 10.1186/s13063-021-05541-w↗
  16. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07927-2↗
  17. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1159/000475477↗
  18. Vitamin D Supplementation is a Promising Therapy for Pancreatic Ductal Adenocarcinoma in Conjunction with Current Chemoradiation Therapy. Co-author DOI 10.1245/s10434-018-6431-8↗
  19. [A Resectable Case of TS-1 Therapy Useful in Distinguishing Primary Lung Cancer from Lung Metastases of Pancreatic Cancer]. Co-author PMID 29362317↗
  20. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-016-1405-6↗
  21. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Co-author DOI 10.1007/s00595-017-1522-x↗
  22. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep42339↗
  23. MicroRNA-181b-5p, ETS1, and the c-Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Co-author DOI 10.1111/cas.13159↗
  24. Two cases of resectable pancreatic cancer diagnosed by open surgical biopsy after endoscopic ultrasound fine-needle aspiration failed to yield diagnosis: case … Co-author DOI 10.1186/s40792-017-0314-2↗
  25. CT Density in the Pancreas is a Promising Imaging Predictor for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-017-5914-3↗
  26. Patients Treated with Preoperative Chemoradiation for Pancreatic Ductal Adenocarcinoma have Impaired Bone Density, a Predictor of Distant Metastasis. Co-author DOI 10.1245/s10434-017-6040-y↗
  27. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes. First author DOI 10.1371/journal.pone.0184901↗
  28. Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000205↗
  29. Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction. Co-author DOI 10.3748/wjg.v21.i40.11396↗
  30. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells. First author DOI 10.3892/ijo.2014.2717↗
  31. Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1093/jjco/hyu143↗
  32. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000159↗
  33. Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Co-author DOI 10.1016/j.pan.2013.06.007↗
  34. Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancer. Co-author DOI 10.1111/cas.12084↗
  35. Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. Co-author DOI 10.5754/hge12974↗
  36. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Co-author DOI 10.1038/onc.2011.59↗
  37. [A case report of port-site metastasis of pancreatic cancer after laparoscope assistted distal pancreatectomy]. First author PMID 22202411↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 33 shared papers, 2011–2026 · strength 3.24
  2. Hidetoshi Eguchi · 32 shared papers, 2011–2026 · strength 3.19
  3. Tadafumi Asaoka · 25 shared papers, 2017–2026 · strength 3.06
  4. Daisaku Yamada · 24 shared papers, 2017–2025 · strength 2.86
  5. Yoshifumi Iwagami · 21 shared papers, 2013–2026 · strength 2.66
  6. Yoshito Tomimaru · 14 shared papers, 2013–2026 · strength 1.83
  7. Hirofumi Akita · 15 shared papers, 2011–2026 · strength 1.81
  8. Hidenori Takahashi · 12 shared papers, 2011–2024 · strength 1.73
  9. Yutaka Takeda · 18 shared papers, 2011–2025 · strength 1.52
  10. Kunihito Gotoh · 15 shared papers, 2017–2023 · strength 1.36
  11. Kazuki Sasaki · 8 shared papers, 2022–2024 · strength 1.27
  12. Masanori Tsujie · 5 shared papers, 2021–2026 · strength 0.87
  13. Osakuni Morimoto · 4 shared papers, 2021–2025 · strength 0.65
  14. Daiki Marukawa · 2 shared papers, 2023–2024 · strength 0.37
  15. Kenta Furukawa · 4 shared papers, 2015–2024 · strength 0.35
  16. Keisuke Toya · 2 shared papers, 2023 · strength 0.32
  17. Shohei Takaichi · 2 shared papers, 2023 · strength 0.32
  18. Masahiro Murakami · 2 shared papers, 2021–2026 · strength 0.32
  19. Hiroaki Nagano · 8 shared papers, 2011–2017 · strength 0.29
  20. Suguru Mitsufuji · 2 shared papers, 2022 · strength 0.27
  21. Manabu Mikamori · 2 shared papers, 2017–2024 · strength 0.27
  22. Hidetoshi Eguchi · 2 shared papers, 2017–2025 · strength 0.26
  23. Masaki Mori · 5 shared papers, 2011–2018 · strength 0.25
  24. Chikato Koga · 2 shared papers, 2011–2026 · strength 0.25
  25. Hiroshi Wada · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.